Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival.

PURPOSE To determine the safety and efficacy of computed tomography (CT)-guided brachytherapy in hepatocellular carcinoma (HCC). METHODS AND MATERIALS A total of 83 patients were recruited, presenting with 140 HCC- lesions. Treatment was performed by CT-guided high-dose-rate (HDR) brachytherapy with an iridium-192 source. The primary endpoint was time to progression; secondary endpoints included local tumor control and overall survival (OS). A matched-pair analysis with patients not receiving brachytherapy was performed. Match criteria included the Cancer of the Liver Italian Program (CLIP) score, alpha-fetoprotein, presence, and extent of multifocal disease. For statistical analysis, Kaplan-Meier and Cox regression were performed. RESULTS Mean and median cumulative TTP for all patients (n = 75) were 17.7 and 10.4 months. Five local recurrences were observed. The OS after inclusion reached median times of 19.4 months (all patients), 46.3 months (CLIP score, 0), 20.6 months (CLIP score, 1) 12.7 months, (CLIP score, 2), and 8.3 months (CLIP score, >or=3). The 1- and 3-year OS were 94% and 65% (CLIP score, 0), 69% and 12% (CLIP score, 1), and 48% and 19% (CLIP score, 2), respectively. Nine complications requiring intervention were encountered in 124 interventions. Matched-pair analysis revealed a significantly longer OS for patients undergoing CT-guided brachytherapy. CONCLUSION Based on our results the study treatment could be safely performed. The study treatment had a beneficial effect on OS in patients with advanced HCC, with respect to (and depending on) the CLIP score and compared with OS in a historical control group. A high rate of local control was also observed, regardless of applied dose in a range of 15 to 25 Gy.

[1]  N. Gilani,et al.  Spontaneous regression of hepatocellular carcinoma is possible and might have implications for future therapies. , 2008, European journal of gastroenterology & hepatology.

[2]  J. Bruix,et al.  Prospective Validation of the Cancer of the Liver Italian Program (CLIP) Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma , 2000, Hepatology.

[3]  P. Wust,et al.  Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. , 2004, Journal of vascular and interventional radiology : JVIR.

[4]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[5]  P. Bachellier,et al.  Surgical resection of hepatocellular carcinoma. Post‐operative outcome and long‐term results in Europe: An overview , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  Guy Brock,et al.  Experience With More Than 500 Minimally Invasive Hepatic Procedures , 2008, Annals of surgery.

[7]  M. Pompili,et al.  Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre , 2005, Gut.

[8]  Alessandro Vitale,et al.  Prospective validation of the Barcelona Clinic Liver Cancer staging system. , 2006, Journal of hepatology.

[9]  J. Hiatt,et al.  Surgical Resection of Hepatocellular Carcinoma , 2008, Cancer journal.

[10]  B. Sangro,et al.  Spontaneous Regression of Hepatocellular Carcinoma: Three Case Reports and a Categorized Review of the Literature , 2009, Digestive Diseases and Sciences.

[11]  P. Wust,et al.  [CT-Guided brachytherapy. A novel percutaneous technique for interstitial ablation of liver metastases]. , 2004, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[12]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[13]  J. Llovet,et al.  Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.

[14]  L. Dawson The evolving role of radiation therapy in hepatocellular carcinoma. , 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[15]  Yi-tao Ding,et al.  Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. , 2009, World journal of gastroenterology.

[16]  P. Wust,et al.  CT-guided interstitial single-fraction brachytherapy of lung tumors: phase I results of a novel technique. , 2005, Chest.

[17]  R. T. Ten Haken,et al.  Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Kagei,et al.  Proton Beam Therapy for Hepatocellular Carcinoma: A Retrospective Review of 162 Patients , 2005, Clinical Cancer Research.

[19]  C. Lieber,et al.  Spontaneous regression of hepatocellular carcinoma. , 1982, Gastroenterology.

[20]  M. Reiser,et al.  Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma , 2007, Digestion.

[21]  L. Dawson,et al.  Radiation therapy for hepatocellular carcinoma , 2006, Cancer.

[22]  J. Bruix,et al.  Nonsurgical treatment of hepatocellular carcinoma , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[23]  David D. Smith,et al.  Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. , 2008, American journal of surgery.

[24]  T. Vogl,et al.  Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. , 2009, European journal of radiology.

[25]  T. Hashimoto,et al.  Proton Beam Therapy for Hepatocellular Carcinoma Patients with Severe Cirrhosis , 2006, Strahlentherapie und Onkologie.

[26]  Zongli Zhang,et al.  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. , 2008, JAMA.

[27]  Peter Wust,et al.  CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. , 2004, International journal of radiation oncology, biology, physics.

[28]  S. Fan,et al.  Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma. , 2009, Journal of hepato-biliary-pancreatic surgery.

[29]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[30]  T. Hashimoto,et al.  Proton beam therapy for hepatocellular carcinoma with limited treatment options , 2006, Cancer.

[31]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[32]  P. Wust,et al.  In vivo assessment of the tolerance dose of small liver volumes after single-fraction HDR irradiation. , 2005, International journal of radiation oncology, biology, physics.

[33]  J. Crowe,et al.  Spontaneous Regression of Hepatocellular Carcinoma , 2008, The American Journal of Gastroenterology.

[34]  G. Maddern,et al.  Radiofrequency ablation of liver tumors: a systematic review. , 2006, Archives of surgery.

[35]  K. Ohara,et al.  Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. , 2007, International journal of radiation oncology, biology, physics.

[36]  Peter Wust,et al.  CT-Guided Interstitial Brachytherapy of Primary and Secondary Lung Malignancies , 2008, Strahlentherapie und Onkologie.

[37]  R. Felix,et al.  Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. , 2004, Journal of vascular and interventional radiology : JVIR.

[38]  Y. Akine,et al.  Proton beam therapy for aged patients with hepatocellular carcinoma. , 2007, International journal of radiation oncology, biology, physics.

[39]  H. Rhim,et al.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies , 2009, Hepatology.

[40]  T. Hashimoto,et al.  Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus , 2005, Cancer.

[41]  L. Lehmkuhl,et al.  CT-guided interstitial brachytherapy in the local treatment of extrahepatic, extrapulmonary secondary malignancies , 2006, European Radiology.

[42]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[43]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[44]  K. Flaherty,et al.  Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. , 2007, Cancer research.

[45]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.